CombiGene initiates restructuring as part of strategic review to maximize shareholder value
The Board of CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that a first step has
The Board of CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that a first step has
The Board of Directors of CombiGene AB (publ) (“CombiGene” or the “Company”) has received proposals for
CombiGene AB (publ) (“CombiGene”, “the Company”) announces today that it intends to sharpen its strategic focus
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces preliminary results from completed analyzes of the latest
CombiGene today announces that the company will regain the global rights for the epilepsy project CG01
CombiGene AB (“CombiGene”, the “Company”) today announces that CEO Jan Nilsson will leave his position as
STOCKHOLM — January 9, 2023. CombiGene AB (“CombiGene”, the “Company”) and the Danish company Zyneyro ApS
STOCKHOLM, October 12, 2021 — CombiGene AB (‘CombiGene’ or the ‘Company’) and Spark Therapeutics, a member
The board of directors of CombiGene AB (publ) (“CombiGene”) has prepared an EU Growth Prospectus relating
The board of directors of CombiGene AB (publ) (“CombiGene”) has today, based on the authorisation from